[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Espad Pharmed\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":61},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100602699","evaluation-of-efficacy-and-safety-of-alcarisa-hyaluronic-acid-produced-by-espad-pharmed-co-for-restoration-of-mid-face-volume-100602699",false,"NCT07126912","Evaluation of Efficacy and Safety of Alcarisa (Hyaluronic Acid Produced by Espad Pharmed Co.) for Restoration of Mid-face Volume","A Single-arm, Before- After Clinical Study to Evaluate the Safety and Efficacy of Alcarisa Hyaluronic Acid Filler (Espad Pharmed Co.) for Restoration of Mid-face Volume","Inclusion Criteria:\n\n* Men and women aged 30 to 65 years\n* Individuals with moderate to significant mid-face volume loss (score 3 to 4) based on changes in MFVDS (in cases of asymmetry between the two sides of the face, the more severe side will be considered)\n* Ability to comply with visit schedules and study procedures\n* Signed the informed consent form and agreed to 6-month follow-up\n\nExclusion Criteria:\n\n* History of Type I hypersensitivity reactions or anaphylaxis\n* Known allergy or sensitivity to any components of the filler, lidocaine, or to proteins from the HA-producing microorganisms (Streptococci)\n* History of hypertrophic or keloid scarring, or bleeding disorders in the injection area\n* Active inflammatory processes, infections, lesions (malignant or benign), or scars in the injection area\n* History of streptococcal diseases (such as recurrent sore throat or acute rheumatic fever) in the past 6 months\n* History of autoimmune\u002Fimmunodeficiency diseases, or use of immunosuppressive drugs during the 6 months prior to or during the study\n* History of surgery or trauma in the injection area within the past 6 months\n* Use of antiplatelet drugs within 72 hours prior to treatment, or anticoagulants within 2 weeks prior to or during treatment\n* Use of drugs that reduce or inhibit hepatic metabolism (e.g., cimetidine, beta-blockers) due to the presence of lidocaine\n* Pregnancy, breastfeeding, or plans to become pregnant in the near future during the study\n* Undergoing or planning to undergo cosmetic treatments in the near future during the study, such as:\n\n  1. Botulinum toxin type A injections below the zygomatic arch during the 6 months prior to study entry\n  2. Previous injections of temporary dermal fillers (e.g., bovine collagen, hyaluronic acid) in the facial area within 1 year prior to study entry\n  3. Use of calcium hydroxyapatite, poly-L-lactic acid, or permanent fillers (e.g., silicone), or fat injections in the injection area at any time before or during the study","ALL","30 Years","65 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","Mid-face volume loss is a factor affecting beauty that makes people feel uncomfortable about themselves. The purpose of this study is to evaluate the efficacy and safety of Hyaluronic Acid injection with the brand name Alcarisa®, manufactured by Espad Pharmed Co., for treatment of this condition.\n\nThe intervention consisted of a single treatment session, injecting 2 to 4 cc of gel into the zygomaticomalar area, and, if deemed by the physician, into the anteromedial cheek and submalar areas on each side of the face.\n\nThe patient underwent digital photography at the following time points: before injection, immediately after injection, and at 4, 12, and 24 weeks post-injection. The physician then used these photographs to evaluate the product's efficacy and safety based on predefined measurements. In addition, participant satisfaction was assessed at the same time intervals.",[27],"Mid Face Volume Deficit","RECRUITING","2025-08-25",{"date":31,"type":32},"2025-09-02","ACTUAL",{"date":34,"type":32},"2025-01-28",{"date":36,"type":21},"2025-10-30",{"name":38,"class":39},"Espad Pharmed","INDUSTRY",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":18,"enrollmentInfo":47,"targetDuration":4,"studyType":22,"phases":49,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":5},"100594032","evaluating-the-efficacy-and-safety-of-embella-deoxycholic-acid-produced-by-espad-pharmed-co-injection-in-the-management-of-superficial-lipomas-100594032","NCT07014163","Evaluating the Efficacy and Safety of Embella (Deoxycholic Acid, Produced by Espad Pharmed Co.) Injection in the Management of Superficial Lipomas","Inclusion Criteria:\n\n1. Men and women aging between 18 to 65 years\n2. Having at least one lipoma (based on clinical and sonographic diagnosis), which is accessible for treatment and assessment and is quantifiable along at least 2 perpendicular diameters and lower than 2 centimeter in depth, with the following characteristics:\n\n   * History of slow growth followed by dormancy\n   * Being stable for at least 6 months\n   * Greatest length by greatest perpendicular width between 4 and 4 square centimeters\n   * Inclusive discrete, oval to rounded in shape, not hard or attached to underlying tissue\n   * Located on the trunk, upper and lower limbs, far from main and vulnerable neurovascular structures\n3. Stable body weight with a body mass index of less than 30 kg\u002Fm² in the past three months\n4. Signed informed consent\n5. Ability to follow study instructions and likely to complete all required visits\n6. Agreement to abstain from any treatment for lipomas during the study\n\nExclusion Criteria:\n\n1. Any medical and physical conditions (for example, high blood pressure or respiratory, cardiovascular, liver, neurological, or thyroid disorders) that, in the opinion of the attending physician, affect the evaluation of the efficacy and safety of the product.\n2. Known allergy or sensitivity to the study medication or its components\n3. Females who are pregnant or breastfeeding, or expecting to conceive children within the projected duration of study\n4. Current enrollment in an investigational drug or device study or participation in such a study within 30 days of entry into this study and for the duration of the study.\n5. Previous treatment for lipomas\n6. Subjects planning a surgical procedure for lipoma during the study or at any time that may affect the evaluation\n7. Subjects with volume deficit due to trauma, abnormalities in adipose tissue related to immune-mediated diseases such as generalized lipodystrophy (e.g., juvenile dermatomyositis), partial lipodystrophy (e.g., Barraquer-Simons syndrome) or HIV-related disease\n8. Evidence of recent alcohol or drug abuse\n9. Medical and\u002For psychiatric problems that are severe enough to interfere with the study results\n10. Known bleeding disorder or receiving medication that will likely increase the risk of bleeding after injection\n11. Having a tendency to develop hypertrophic scarring\n12. Having a history of anaphylaxis or allergy to lidocaine (or any amide-based anesthetics), hyaluronic acid products, or Streptococcal protein\n13. Having an active inflammation, dermatoses, infection, cancerous or precancerous lesion, or unhealed wound in the site of lipoma\n14. Having a condition or being in a situation that, in the investigator's opinion, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study","18 Years",{"count":48,"type":21},10,[24],"Lipoma is a relatively common, slow-growing mesenchymal neoplasm originating from adipose tissue. Patients seek treatment for lipomas for various reasons, such as concerns about their growth and spread, aesthetic issues, or worries about the compressive effects of the lipoma. Lipomas are typically removed surgically through excision, which can have complications including bleeding, infection, scarring, and recurrence. Other mentioned treatment methods include liposuction, laser, and medicinal approaches.\n\nPurified synthetic deoxycholic acid has been introduced as the first pharmacological intervention approved by the FDA for the reduction of submental fat. Deoxycholic acid is a type of bile acid that, due to its ability to cause non-selective cell lysis and disruption of adipocyte membranes (adipocytolysis), leads to emulsification of fat in the intestine.\n\nThis is an interventional (pre-post), single-arm, and open-label study to evaluate the efficacy and safety of Embella (Deoxycholic acid, produced by Espad Pharmed Co.) for the management of superficial lipomas.",[52],"Lipoma","2025-06-09",{"date":55,"type":32},"2025-06-10",{"date":57,"type":32},"2024-05-21",{"date":59,"type":21},"2026-06-20",{"name":38,"class":39},""]